Imatinib: a designer drug, another cutaneous complicationDICKENS, E; LEWIST, F; BIENZ, N et al.Clinical and experimental dermatology (Print). 2009, Vol 34, Num 5, pp 603-604, issn 0307-6938, 2 p.Article

Imatinib-induced pseudoporphyriaTIMMER-DE MIK, L; KARDAUN, S. H; KRAMER, M. H. H et al.Clinical and experimental dermatology (Print). 2009, Vol 34, Num 6, pp 705-707, issn 0307-6938, 3 p.Article

Congestive heart failure during imatinib mesylate treatmentTURRISI, Gina; MONTAGNANI, Francesco; GROTTI, Simone et al.International journal of cardiology. 2010, Vol 145, Num 1, pp 148-150, issn 0167-5273, 3 p.Article

In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitorsBRIEGER, Angela; BOEHRER, Simone; KAI UWE CHOW et al.Biochemical pharmacology. 2004, Vol 68, Num 1, pp 85-93, issn 0006-2952, 9 p.Article

Langerhans Cell Histiocytosis: Treatment Failure With ImatinibWAGNER, Christina; MOHME, Henrik; KRÖMER-OLBRISCH, Tanja et al.Archives of dermatology (1960). 2009, Vol 145, Num 8, pp 949-950, issn 0003-987X, 2 p.Article

Evaluation of CML model cell lines and imatinib mesylate response : Determinants of signaling profilesWETZEL, Randy; GOSS, Valerie L; NORRIS, Brett et al.Journal of immunological methods. 2005, Vol 305, Num 1, pp 59-66, issn 0022-1759, 8 p.Conference Paper

Neoadjuvant Imatinib Therapy for Dermatofibrosarcoma ProtuberansHAN, Anne; CHEN, Elbert H; NIEDT, George et al.Archives of dermatology (1960). 2009, Vol 145, Num 7, pp 792-796, issn 0003-987X, 5 p.Article

Clinical resistance to imatinib: mechanisms and implicationsHOCHHAUS, Andreas; HUGHES, Timothy.Hematology/oncology clinics of North America. 2004, Vol 18, Num 3, issn 0889-8588, ix, 641-656 [17 p.]Article

Toxidermie à l'imatinib suivie d'une toxidermie au nilotinib = Successive cutaneous adverse reactions to nilotinib and imatinib in a single patientLAMCHAHAB, M; QACHOUH, M; HALI, F et al.Annales de dermatologie et de vénéréologie. 2012, Vol 139, Num 12, pp 828-831, issn 0151-9638, 4 p.Article

Polycythemia From Mast Cell Activation Syndrome: Lessons LearnedAFRIN, Lawrence B; HAMM, L. Lee.The American journal of the medical sciences (Print). 2011, Vol 342, Num 1, pp 44-49, issn 0002-9629, 6 p.Article

Diferentes alteraciones genéticas causan diferentes melanomas y nuevas posibilidades terapéuticas = New Therapies Targeting the Genetic Mutations Responsible for Different Types of MelanomaBOTELLA-ESTRADA, R; SANMARTIN JIMENEZ, O.Actas dermo-sifiliográficas (Ed. impresa). 2010, Vol 101, Num 5, pp 394-400, issn 0001-7310, 7 p.Article

L'imatinib mésilate: un nouveau traitement de la sclérodermie ? = A potential role for imatinib in the treatment of systemic sclerosisKLUGER, N.Images en dermatologie. 2009, Vol 2, Num 3, pp 105-106, issn 1964-4167, 2 p.Article

Hyperéosinophilies et affections hématologiques = Hematological disorders and hypereosinophiliasMALFUSON, J.-V; FAGOT, T; KONOPACKI, J et al.La Revue de médecine interne (Paris). 2009, Vol 30, Num 4, pp 322-330, issn 0248-8663, 9 p.Article

Dermatofibrosarcoma protuberans = Dermatofibrosarcoma protuberansUGUREL, S.Hautarzt. 2008, Vol 59, Num 11, pp 933-940, issn 0017-8470, 8 p.Article

Investigation of the effect of the c-kit inhibitor Glivec on isolated guinea-pig detrusor preparationsKUBOTA, Yasue; KAJIOKA, Shunichi; BIERS, Suzanne M et al.Autonomic neuroscience : basic & clinical. 2004, Vol 115, Num 1-2, pp 64-73, issn 1566-0702, 10 p.Article

A Case of Cutaneous Rosai-Dorfman Disease Refractory to Imatinib TherapyGEBHARDT, Carl; AVERBECK, Marco; PAASCH, Uwe et al.Archives of dermatology (1960). 2009, Vol 145, Num 5, pp 571-574, issn 0003-987X, 4 p.Article

Another look at imatinib mesylateSTREBHARDT, Klaus; ULLRICH, Axel.The New England journal of medicine. 2006, Vol 355, Num 23, pp 2481-2482, issn 0028-4793, 2 p.Article

Loss of skin pigment caused by imatinib therapyMCPARTLIN, S; LEACH, M.British journal of haematology. 2005, Vol 129, Num 4, issn 0007-1048, p. 448Article

Imatinib (Gleevec®)-induced hepatotoxicityAYOUB, Walid S; GELLER, Stephen A; TRAN, Tram et al.Journal of clinical gastroenterology. 2005, Vol 39, Num 1, pp 75-77, issn 0192-0790, 3 p.Article

The GIST paradigm: lessons for other kinase-driven cancersANTONESCU, Cristina R.Journal of pathology (Print). 2011, Vol 223, Num 2, pp 251-261, issn 0022-3417, 11 p.Article

Dermatofibrosarcoma Protuberans of the Vulva: A Clinicopathologic and Immunohistochemical Study of 13 CasesEDELWEISS, Marcia; MALPICA, Anais.The American journal of surgical pathology. 2010, Vol 34, Num 3, pp 393-400, issn 0147-5185, 8 p.Article

The tyrosine kinase inhibitor imatinib mesylate delays prion neuroinvasion by inhibiting prion propagation in the peripheryYUN, Seong-Wook; ERTMER, Alexa; FLECHSIG, Eckhard et al.Journal of neurovirology. 2007, Vol 13, Num 4, pp 328-337, issn 1355-0284, 10 p.Article

Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: Report of two successfully treated casesALCEDO, Juan Carlos; FABREGA, José Manuel; AROSEMENA, Juan Ramon et al.Head & neck. 2004, Vol 26, Num 9, pp 829-831, issn 1043-3074, 3 p.Article

Oral lichenoid eruption associated with imatinib treatmentGOMEZ FERNANDEZ, Cristina; SENDAGORTA CUDOS, Elena; CASADO VERRIER, Beatriz et al.EJD. European journal of dermatology. 2010, Vol 20, Num 1, pp 127-128, issn 1167-1122, 2 p.Article

Recherche des anticancéreux : passé et présent = Search for the anticancer agents: past and presentPIERRE, A.Annales pharmaceutiques françaises. 2005, Vol 63, Num 1, pp 10-16, issn 0003-4509, 7 p.Conference Paper